This work is built upon the combination of the polyarginine (R9) CPP with the GRP78‐targeting (W1) peptide, for improving cell uptake efficiency and specificity directly within the GRP78 overexpressing (DU145) prostate cancer cells. Here, HSPA5 is linked to prostate carcinoma.